Todos Medical Ltd. announced that it signed an amendment to its agreement with its 3CL protease biology theranostics partner NLC Pharma Ltd. As a consequence, NLC Pharma has assigned ownership of all relevant intellectual property to majority-owned joint venture 3CL Pharma Ltd. The assignment includes the patent applications for dual mechanism Phase 2 therapeutic drug candidate Tollovir, commercial-stage 3CL protease inhibitor immune support supplement Tollovid, and 3CL protease biomarker test TolloTest for SARS-CoV-2 infectivity monitoring and PASC/Long COVID viral persistence assessment. 3CL Pharma Ltd. is now preparing to launch a crowdfunding campaign to fund the necessary requirements for an Emergency Use Authorization submission to the US FDA for Tollovir in the treatment of hospitalized COVID-19 patients, the clinical development of Tollovir, Tollovid and TolloTest in Long COVID, as well as a national marketing campaign for Tollovid to support US sales. Todos is targeting a crowdfunding launch ahead of October 6th, 2022 in alignment with the FDA's Adcom meeting for Veru, Inc.'s sabizabulin which is another COVID-19 drug seeking approval in the hospitalized setting.